Drugs / Quadrivalent Inactivated Influenza High Dose
Quadrivalent Inactivated Influenza High Dose
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04969276 | Jul 2021 → Feb 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Quadrivalent Inactivated Influenza High Dose | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04969276 ↗ |
| Modality | Vaccine | “high-dose quadrivalent influenza vaccine” NCT04969276 ↗ |
| Route | Intramuscular | “Intramuscular injection” NCT04969276 ↗ |